<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00409227</url>
  </required_header>
  <id_info>
    <org_study_id>165/05</org_study_id>
    <nct_id>NCT00409227</nct_id>
  </id_info>
  <brief_title>Does Treatment With Alfuzosin Increase Success Rates of (SWL) Shock Wave Lithotripsy</brief_title>
  <official_title>Prospective Randomized Placebo Controlled Blinded Study to Evaluate the Efficacy of Alfuzosin (Alpha Blocker) on the Success Rates Following SWL.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In latest literature more evidence is available about the positive effect of alpha blocker on
      stone expulsion from the ureter. Patients benefit from less pain and shortening time to stone
      expulsion. Our study is design to evaluate whether alfuzosin improves the stone free out come
      following SWL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients undergoing SWL are included in study. Exclusion criteria: Patient with
      radio-lucent stone, patients treated with calcium channel blockers, alpha blockers, steroids,
      patients with contraindication to alpha blocker treatment, postural hypotension patents with
      abnormal liver function tests.

      Patient will be recruited to the study prospectively. Following signature on inform consent
      patients will be randomized into 2 groups. One group will be treated with alfuzosin 10mg a
      day and the control group with placebo. Treatment will be initiated following the lithotripsy
      treatment.

      Parameters for investigation includes: demographic and personal data, stone size and location
      (obtained by CT or KUB), pain control medication and visual analogue scale assessment of
      pain, side effects, clinical squeals, stone free out come. Follow up evaluation will be at 1
      week, 1 month, and 3 months post treatment. Success will be defined following CT evaluation
      at 3 months. Treatment ends at stone free achievement or at 3 months.

      Endpoints:Stone free rate, time to stone free, side effect.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2006</start_date>
  <primary_completion_date type="Anticipated">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>use of pain control medication stone free rates</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>pain visual analogue scale</measure>
    <time_frame>3 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>side effects</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>stone free rate</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>time to stone free status</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>need for secondary procedures</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>auxiliary procedures</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Urolithiasis</condition>
  <condition>Nephrolithiasis</condition>
  <condition>Ureterolithiasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>double blind placebo control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo control blinded arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alpha blocker-alfuzosin</intervention_name>
    <description>P.O. alfuzosin 10 mg once a day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo once a day for 3 months or stone free</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing shock wave lithotripsy treatment for urolithiasis.

        Exclusion Criteria:

          -  patients with abnormal liver function, postural hypotension, alpha-blocker treatment,
             sensitivity to alpha-blockers, radio-lucent stone, calcium channel blocker treatment,
             steroids treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yoram I siegel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endourology unit Urology department Assaf harofeh MC.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yoram I siegel, MD</last_name>
    <phone>972-577-345408</phone>
    <email>ysiegel@asaf.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Endourology unit Urology department Assaf Harofeh MC</name>
      <address>
        <city>Zerifin</city>
        <zip>40700</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yoram i siegel, MD</last_name>
      <phone>972-577-345408</phone>
      <email>ysiegel@asaf.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>yoram i siegel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>yaniv shilo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2006</study_first_submitted>
  <study_first_submitted_qc>December 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2006</study_first_posted>
  <last_update_submitted>June 17, 2008</last_update_submitted>
  <last_update_submitted_qc>June 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>Yoram I Siegel MD</name_title>
    <organization>Assaf Harofeh MC</organization>
  </responsible_party>
  <keyword>swl</keyword>
  <keyword>lithotripsy</keyword>
  <keyword>stone disease</keyword>
  <keyword>urolithiasis</keyword>
  <keyword>nephrolithiasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Urolithiasis</mesh_term>
    <mesh_term>Ureterolithiasis</mesh_term>
    <mesh_term>Ureteral Calculi</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alfuzosin</mesh_term>
    <mesh_term>Adrenergic alpha-Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

